Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) With 90Y-DOTATOC in Pancreatic Neuroendocrine Tumours.

NCT05568017 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT05568017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05568017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) With 90Y-DOTATOC in Pancreatic Neuroendocrine Tumours.
Lead sponsor
European Institute of Oncology
Phase
Phase 2
Overall status
Terminated
Start date
September 15, 2020
Completion date
November 11, 2024
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neuroendocrine tumor